The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals